MAGENTA Oocyte Scores, Morphokinetics and Live Birth – Future Fertility
Future Fertility shared a post on LinkedIn:
“This week, we’re highlighting our joint research with Kato Ladies Clinic, published in Reproductive BioMedicine Online. This study explores how MAGENTA oocyte quality scores correlate to early embryonic development and treatment outcomes, while validating our technology in a Japanese patient population and utilizing minimal stimulation protocols.
Study highlights:
- Retrospective analysis of 2,785 oocytes across 1,340 minimal stimulation IVF cycles
- Lower MAGENTA scores correlated with delayed morphokinetics and reduced developmental potential
- Higher mean sum of MAGENTA scores correlated positively with live birth rate per retrieval
- Findings support performance in minimal stimulation protocols, reinforcing use across diverse clinical settings
Why this matters:
- These findings demonstrate that key signals of embryo potential already exist at the oocyte stage, and that AI can help surface these signals earlier and more objectively to support counselling and treatment planning.
- This work builds upon our continued efforts to further validate and expand correlations between MAGENTA scores and downstream endpoints.
Congratulations to all authors and collaborators involved in this work:
Nanoha F., Kenji Ezoe, Tetsuya Miki, Tsubasa Takahashi, Laís Vanzella, PhD, Natalie Mercuri, Jullin Fjeldstad, Parisa Mojiri, Dan Nayot, Tomoko Kuroda, Keiichi Kato
Read the full article on RBMO: ‘Artificial intelligence-driven oocyte scores link early morphokinetics to embryo outcomes following intracytoplasmic sperm injection’
Artwork by Diana Tain.”

Proceed to the pages attahced to the post.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Nov 2, 2026, 17:08Elena Milner: The 2nd Class of the School of Embryology Is Already in Full Swing
-
Nov 2, 2026, 17:05November Is National Diabetes Month – PCOS Awareness Association
-
Nov 2, 2026, 17:04Thanos Papathanasiou: Are We Preparing Patients for the IVF Cycle, or for the IVF Journey?
-
Nov 2, 2026, 17:02Anna Morales: Why Is It So Hard to Build in Women’s Health?
-
Nov 2, 2026, 16:59Rickard Ericsson: Honored to Take on the Role of Interim CEO of the Vitrolife Group
-
Nov 2, 2026, 16:56Mohammed Nasur: 1 Small Simulation, A Bigger Purpose
-
Nov 2, 2026, 16:54Carlos Guerrero: Presenting Our Latest Research on AI and Embryo Assessment at ASRM 2026
-
Nov 2, 2026, 16:52Sarah Lewen: My 1st ASRM Is Officially Complete
-
Nov 2, 2026, 16:49Jemma Garratt: Taking on the Role of Kind IVF and Data Science Manager at London Women’s Clinic
